中国卫生经济
中國衛生經濟
중국위생경제
CHINESE HEALTH ECONOMICS
2014年
3期
39-41
,共3页
药品目录%住院患者%用药变化
藥品目錄%住院患者%用藥變化
약품목록%주원환자%용약변화
national reimbursement drug list%inpatient%change of drug use
目的：了解药品目录调整对参保患者待遇、医保基金支出以及具体药品市场销售的影响。方法：以全国参保住院患者医疗服务利用情况调查数据为基础，进一步进行统计分析2009-2011年的用药变化情况。结果：2011年全国参保住院患者的药品费用约为1327亿元，较2009年增长了37%，目录内药品费用占整体药品费用的比例稳定在76%左右。新增药品2011年费用为135亿元，较2009年增长了98%。结论：目录调整对于参保患者住院用药整体费用的增长影响不大，但导致了目录内药品费用结构发生变化，部分新增品种费用增长明显。今后目录调整可以逐步从保障基本用药转到促进临床合理用药上来。
目的：瞭解藥品目錄調整對參保患者待遇、醫保基金支齣以及具體藥品市場銷售的影響。方法：以全國參保住院患者醫療服務利用情況調查數據為基礎，進一步進行統計分析2009-2011年的用藥變化情況。結果：2011年全國參保住院患者的藥品費用約為1327億元，較2009年增長瞭37%，目錄內藥品費用佔整體藥品費用的比例穩定在76%左右。新增藥品2011年費用為135億元，較2009年增長瞭98%。結論：目錄調整對于參保患者住院用藥整體費用的增長影響不大，但導緻瞭目錄內藥品費用結構髮生變化，部分新增品種費用增長明顯。今後目錄調整可以逐步從保障基本用藥轉到促進臨床閤理用藥上來。
목적：료해약품목록조정대삼보환자대우、의보기금지출이급구체약품시장소수적영향。방법：이전국삼보주원환자의료복무이용정황조사수거위기출，진일보진행통계분석2009-2011년적용약변화정황。결과：2011년전국삼보주원환자적약품비용약위1327억원，교2009년증장료37%，목록내약품비용점정체약품비용적비례은정재76%좌우。신증약품2011년비용위135억원，교2009년증장료98%。결론：목록조정대우삼보환자주원용약정체비용적증장영향불대，단도치료목록내약품비용결구발생변화，부분신증품충비용증장명현。금후목록조정가이축보종보장기본용약전도촉진림상합리용약상래。
Objective:To understand the impact of adjusting national drug reimbursement list(NDRL) have on the benefits of patient covered by Basic Health Insurance ( BHI ) , medical insurance fund expenditure and specific drug marketing . Methods: Based on the survey data of medical service utilization situation of national inpatients participated BHI, to summarize and analyze the change of drug usage from 2009 to 2011. Results: In 2011, the drug expense of the national inpatient covered by BHI is approximately 132.7 billion yuan, increased by 37% compared to that of 2009; among which, the expense of entry drug accounts for about 76% out of the total drug use. In 2011, new increased expense on drug use is 13.5 billion, which increased to 98% compared to that of 2009. Conclusion:Adjustment of NDRL had little effect on total drug expenses increasing, but lead changes of the drug expense structure; and expense on some new entry drugs increased obviously. The focus of future adjustment of NRDL could gradually transfer from guaranteeing on basic medicine use to the promotion on clinical rational drug use.
